Dr. Pavic reports favorable outcomes from masitinib trial for mCRPC

In this video, Michel Pavic, MD, discusses how the combination of masitinib with docetaxel could be a new first-line treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC) and alkaline phosphatase levels less than or equal to 250 IU/mL. Pavic is an oncologist and head of the hematology-oncology service at CIUSSS de l’Estrie (CHUS) and a professor of medicine and health sciences at the University of Sherbrooke, Quebec, Canada.